^
    Back
    Association details:
    Biomarker:BRAF V600
    Cancer:Non Small Cell Lung Cancer
    Drug:Zelboraf (vemurafenib) (BRAF inhibitor, BRAF V600E inhibitor) +
    Kolupin (tunlametinib) (MEK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    A phase II clinical study evaluating the efficacy and safety of HL-085 capsules in combination with vemurafenib for the treatment of patients with BRAF V600E-mutant locally advanced or metastatic non-small cell lung cancer.

    Excerpt:
    ......
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ESMO 2023
    Title:

    1378P - Efficacy and safety of tunlametinib (HL-085) combined with vemurafenib in patients with advanced BRAF V600-mutated solid tumors: A multicenter, phase I study

    Published date:
    10/16/2023
    Excerpt:
    33 pts with non-small cell lung cancer (NSCLC) have been evaluated for response. The objective response rate (ORR) was 60.6% (95%CI: 42.1%, 77.1%), a median duration of response (DoR) was 11.3 months (95% CI: 3.9, NE), and a median progression free survival (PFS) was 11.7 months (95% CI: 5.6, NE)....Tunlametinib in combination with vemurafenib showed promising antitumor activity and manageable safety profile in pts with BRAF V600-mutated solid tumors.
    Trial ID:
    NCT03781219